224 related articles for article (PubMed ID: 32691037)
1. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
[TBL] [Abstract][Full Text] [Related]
2. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
3. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
4. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
Packnett ER; Winer IH; Oladapo A; Wojdyla M
Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
Krilov LR; Anderson EJ
J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
[TBL] [Abstract][Full Text] [Related]
6. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
7. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
[TBL] [Abstract][Full Text] [Related]
8. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
10. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
[TBL] [Abstract][Full Text] [Related]
11. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
12. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
14. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
[No Abstract] [Full Text] [Related]
15. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.
Suh M; Movva N; Jiang X; Reichert H; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S184-S194. PubMed ID: 35968879
[TBL] [Abstract][Full Text] [Related]
16. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
Anderson EJ; Carbonell-Estrany X; Blanken M; Lanari M; Sheridan-Pereira M; Rodgers-Gray B; Fullarton J; Rouffiac E; Vo P; Notario G; Campbell F; Paes B
Pediatr Infect Dis J; 2017 Feb; 36(2):160-167. PubMed ID: 27755464
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
18. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
Suh M; Movva N; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S195-S212. PubMed ID: 35968876
[TBL] [Abstract][Full Text] [Related]
20. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]